非小细胞肺癌非耐药蛋白基因表达与临床疗效关系的研究

Relationship between the clinical efficacy and expression of lung cancer resistance protein genes in non-small cell lung cancer

目的探讨肺耐药蛋白(LRP)基因在非小细胞肺癌(NSCLC)气管镜活检组织或淋巴结活检组织中的表达与其临床疗效的关系。方法应用免疫组织化学S-P技术对19例非小细胞肺癌气管镜活检组织和28例肺癌转移的淋巴结活检组织进行LRP表达水平的检测,并观察其经NP方案化疗2个周期后的临床疗效。结果非小细胞肺癌LRP的表达阳性率为61.70%;在肺腺癌和肺鳞癌中的表达阳性率分别为76.92%和42.86%;LRP在两组间的表达有显著性差异(P<0.05)。LRP表达水平在TNM分期中差异无显著性(P>0.05);经2个周期标准NP方案化疗后总有效率为42.55%,其中LRP表达阳性和阴性的临床有效率分别为24.14%和72.22%,两组间存在显著性差异(P<0.05)。结论LRP在非小细胞肺癌中存在不同程度的表达,阳性者化疗疗效明显高于阴性者。

Objective To investigate the relationship between the expression level of lung cancer resistance protein （LRP） and the clinical efficacy on non-small cell lung cancer by bronchoscopy or lymphaden biopsy tissues.Methods The expression of LRP was detected in 19 cases of lung cancer tissues through bronchoscopy biopsy and in 28 cases of lung cancer lymphaden biopsy tissues by streptavidin-biotin-peroxidase（S -P） immunohistochemistry technique,and evaluated their clinical effects after two of cycles of NP chemiotherapy treated.Results The positive expression rates of LRP on non-small cell lung cancer was 61.70%.The expression positive rates of LRP in the adenocarcinoma and squamous carcinoma were 76.92%and 42.86%respectively.There was statistic difference in LRP expression compared with adenocarcinoma and squamous carcinoma（P0.05）.No significance of difference was observed in LRP expression positive rates in different TNM staging of lung cancer（All P0.05）.The total clinical effective rates was 42.55%after two cycles chemiotherapy treated by NP methods and the clinical effective rates were 24.14%and 72.22%,respectively,between the positive expression of LRP and negative expression of LRP,and there was statistic difference in those two groupes.Conclusions LRP expression differently in non-small cell lung cancer and in adenocarcinoma and squamous carcinoma.The clinical efficacy is also differewt between the positive expression of LRP and negative expression of LRP（P0.01）.